Oncologic Outcomes and Toxicities of Salvage Treatment in Patients With Locoregionally Recurrent Breast Cancer

Condition(s) studied

Investigational drug(s) / intervention(s)

Salvage treatment (surgery and/or radiation therapy): Appropriate salvage treatment (surgery and/or radiation therapy) will be selected by the treating clinicians considering the disease status.

Study summary

The purpose of this study is to evaluate clinical outcomes and adverse events of salvage treatment for locoregional recurrence of breast cancer.

The main questions it aims to answer are:

* Clinical outcomes after salvage treatment for locoregional recurrence
* Adverse events and quality of life after salvage treatment for locoregional recurrence
* Patient characteristics and treatment specifics which are related to the clinical outcomes and/or adverse events
* Molecular signature associated with treatment resistance

Participants will be assessed by multi-dimensional methods during and after radiation therapy:

* Assessment for the disease status (disease-free or recurrence) including physical and radiologic examination
* Assessment for the adverse events according to CTCAE version 5.0
* Assessment for the molecular signature using residual tissue after pathologic diagnosis
* Assessment for the quality of life using questionnaires (BREAST-Q)

Eligibility

Primary outcome measure(s)

• Progression-free survival — 5 years from the initiation of the salvage therapy
  The event for progression-free survival was defined as any disease progression or breast cancer-related death.
• Rate of adverse events — 5 years from the initiation of the salvage therapy
  Adverse events related to the salvage therapy will be reported and incidence rate will be calculated.

Trial sites (1)

More Samsung Medical Center trials in South Korea

Other trials for the same condition